LTRN7:30 AMLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLClanternpharma.com
LTRN4:01 PMLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updateslanternpharma.com
LTRN4:05 PMLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investorlanternpharma.com
LTRN8:00 AMLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investorlanternpharma.com
LTRN4:30 PMLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026lanternpharma.com
LTRN9:01 AMLantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™lanternpharma.com
LTRN8:50 AMLantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globallylanternpharma.com
LTRN7:50 AMLantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debutlanternpharma.com
LTRN8:05 AMEmerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicitylanternpharma.com
LTRN8:31 AMLantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22lanternpharma.com
LTRN8:10 AMLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026lanternpharma.com
LTRN4:05 PMLantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updateslanternpharma.com
LTRN7:23 PMLantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Reportlanternpharma.com
LTRN7:29 AMLantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001lanternpharma.com
LTRN4:30 PMLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETlanternpharma.com